-

IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025

Global Leading Excipient Supplier to Highlight Innovations in Oral Disintegrating Tablets, Controlled Release Formulations, and Low-Nitrite Solutions

TOKYO--(BUSINESS WIRE)--IFF (NYSE:IFF) Pharma Solutions will showcase its cutting-edge excipient technologies at CPHI Japan 2025. The IFF Pharma Solutions team will highlight its innovations in oral disintegrating tablets (ODTs), controlled-release formulations, and novel complex formulations at booth 5K-21, Tokyo Big Sight East Halls 4-6, April 9-11.

“IFF Pharma Solutions is committed to redefining drug delivery through material science innovation,” said Frank Zhao, commercial leader, IFF Pharma Solutions, Asia Pacific. “At CPHI Japan, we will showcase technologies designed to elevate patient outcomes while streamlining pharmaceutical production.”

As a global leading pharmaceutical excipient partner, IFF Pharma Solutions will highlight some of its latest innovations, including:

Oral Disintegrating Tablet (ODT) Solutions

  • The ODT market is expanding rapidly, requiring tablets that dissolve quickly for easy administration to children and elderly patients. Incorporating super disintegrants into ODT formulations is essential, as these agents enhance dissolution speed and improve patient compliance. Ac-Di-Sol®, a leading super disintegrant, offers equivalent disintegration efficacy to polyvinylpolypyrrolidone (PVPP).

Controlled Release (C) Portfolio

  • METHOCEL™ Hydroxypropyl methylcellulose (HPMC): Enables consistent and controlled delivery of medication, enhancing therapeutic efficacy and patient compliance through customizable HPMC.
  • ETHOCEL™ Ethylcellulose: Water-resistant barrier coatings for targeted drug delivery and taste masking in modified-release tablets.
  • POLYOX™ Polyethylene Oxide: High-swell matrices for osmotic delivery and abuse-deterrent systems, supporting osmotic pump technology and modified-release matrix formulations.

Low-Nitrite Solutions

  • As a low-nitrite microcrystalline cellulose solution, Avicel® PH LN reduces nitrosamine formation risks in oral solid dosages, ensuring compliance with Japan’s stringent regulatory standards.
  • IFF Pharma Solutions expands its low-nitrite excipient portfolio by introducing Low Nitrite METHOCEL™, tailored to help mitigate the risk of nitrosamine formation in drugs.

Combining its deep expertise in excipients, innovation capabilities, and regulatory services, IFF Pharma Solutions offers an integrated solutions platform for customer support at every step of their formulation journeys. To learn more about our broad portfolio and proven expertise, visit https://pharma.iff.com.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Contacts

Anson Fan
Regional Communications Specialist
+ 86 13756468374
anson.fan@iff.com

IFF



Contacts

Anson Fan
Regional Communications Specialist
+ 86 13756468374
anson.fan@iff.com

More News From IFF

IFF Opens New State-of-the-art Office in Hyderabad, India

HYDERABAD, India--(BUSINESS WIRE)--IFF (NYSE: IFF)--a global leader in flavors, fragrances, food ingredients, health and biosciences—has officially relocated its Global Business Services (GBS) center in Hyderabad to a newly constructed, state-of-the-art facility. This move marks a significant step in IFF’s strategy to drive operational excellence and innovation through agile corporate functions. The new 75,000 sq. ft. office located in Hyderabad’s prime financial district, is designed to accomm...

IFF Appoints Virginia “Gina” Drosos to Board of Directors

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. “We are very pleased to welcome Gina to the IFF board,” said Kevin O’Byrne, chair of the board. “Gina brings extensive relevant experience, deep...

IFF Unveils Game-Changing Outlook on GLP-1 Consumers

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is reshaping the sensory experience and nutritional needs associated with eating and drinking. The report outlines how food and beverage manufacturers can better support this emerging consumer segment with products that align with their evolving preferences. “IFF is empowering our customers to lead the next w...
Back to Newsroom